Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML, .
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Neurology. 2008 Nov 18;71(21):1702-8.
PubMed.
It would be appropriate to try doing a trial of IGF-1 BP3
(Iplex) at a
higher dose. As ALS patients, many of us do not have two years
to waste on
stupidity. I used Iplex briefly before the lawsuit rendered it
unavailable. My "anecdotal" evidence supported slight improvement
in a short period of
time. Worth a shot when it comes to people waiting to die,
isn't it?
Comments
It would be appropriate to try doing a trial of IGF-1 BP3
View all comments by Deborah Gattoni(Iplex) at a
higher dose. As ALS patients, many of us do not have two years
to waste on
stupidity. I used Iplex briefly before the lawsuit rendered it
unavailable. My "anecdotal" evidence supported slight improvement
in a short period of
time. Worth a shot when it comes to people waiting to die,
isn't it?
Make a Comment
To make a comment you must login or register.